Skip to main navigation Skip to search Skip to main content

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials

  • John Nikitas
  • , Parsa Jamshidian
  • , Alison C. Tree
  • , Emma Hall
  • , David Dearnaley
  • , Jeff M. Michalski
  • , W. Robert Lee
  • , Paul L. Nguyen
  • , Howard M. Sandler
  • , Charles N. Catton
  • , Himanshu R. Lukka
  • , Luca Incrocci
  • , Wilma Heemsbergen
  • , Floris J. Pos
  • , Soumyajit Roy
  • , Shawn Malone
  • , Eric Horwitz
  • , Jessica Karen Wong
  • , Stefano Arcangeli
  • , Giuseppe Sanguineti
  • Tahmineh Romero, Yilun Sun, Michael L. Steinberg, Luca F. Valle, Joanne B. Weidhaas, Daniel Spratt, Donatello Telesca, Amar U. Kishan*
*Corresponding author for this work
  • David Geffen School of Medicine
  • University of Pennsylvania
  • University of California at Los Angeles
  • Institute of Cancer Research (ICR), London
  • Royal Marsden NHS Foundation Trust
  • Washington University School of Medicine in St. Louis
  • Duke University
  • Harvard Medical School
  • Cedars-Sinai Medical Center
  • Princess Margaret Hospital Cancer Centre
  • Hamilton Health Sciences
  • Netherlands Cancer Institute
  • Rush University Medical Center (Chicago)
  • Case Western Reserve University School of Medicine
  • University of Ottawa
  • Fox Chase Cancer Center
  • University of Milan - Bicocca
  • IRCCS Istituti fisioterapici ospitalieri - Istituto Regina Elena
  • VA Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)
151 Downloads (Pure)

Abstract

Background: 

The association between acute and late toxicity following prostate radiotherapy has not been well studied using data from multiple randomised clinical trials and fractionation schedules. We aimed to characterise the relationship between acute and late genitourinary and gastrointestinal toxicity among patients receiving conventionally fractionated or moderately hypofractionated prostate radiotherapy. 

Methods: 

This was an individual patient data meta-analysis that identified randomised phase 3 trials of conventionally fractionated or moderately hypofractionated prostate radiotherapy in the Meta-Analysis of Randomized trials in Cancer of the Prostate (MARCAP) Consortium that had individual-level acute and late toxicity data available and were available before Dec 1, 2023. Trials without individual patient data were excluded. Data were provided to MARCAP by study investigators. The associations between acute (≤3 months after radiotherapy) and late (>3 months after radiotherapy) grade 2 or greater genitourinary and gastrointestinal toxicities were assessed using adjusted generalised linear mixed models (adjusted for age, androgen deprivation therapy status, type of radiotherapy, radiation dose, and radiation schedule). In the subset of trials that collected Expanded Prostate Cancer Index Composite quality of life (QOL) evaluations, the association between acute genitourinary and gastrointestinal toxicity and decrements at least twice the minimal clinically important difference (MCID) for urinary and bowel QOL were also evaluated. 

Findings: 

Six of 26 available trials met all the eligibility criteria. 6593 patients were included (conventionally fractionated: n=4248; moderately hypofractionated: n=2345). Median follow-up was 72 months (IQR 61–94). Acute grade 2 or greater genitourinary toxicity was associated with both late grade 2 or greater genitourinary toxicity (odds ratio 2·20 [95% CI 1·88–2·57], p<0·0001) and decrement at least twice the MCID in urinary QOL (1·41 [1·17–1·68], p=0·0002). Acute grade 2 or greater gastrointestinal toxicity was associated with both late grade 2 or greater gastrointestinal toxicity (2·53 [2·07–3·08], p<0·0001) and decrement at least twice the MCID in bowel QOL (1·52 [1·26–1·83], p<0·0001). 

Interpretation: 

Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity. 

Original languageEnglish
Pages (from-to)378-386
Number of pages9
JournalThe Lancet Oncology
Volume26
Issue number3
Early online date30 Jan 2025
DOIs
Publication statusPublished - Mar 2025

Bibliographical note

Publisher Copyright:
© 2025 Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials'. Together they form a unique fingerprint.

Cite this